CORE LABS INC (CLB)
(Delayed Data from NYSE)
$19.21 USD
+0.03 (0.16%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $19.21 0.00 (0.00%) 7:16 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
CLB 19.21 +0.03(0.16%)
Will CLB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLB
SLB and AWS Partner to Boost Digital and Low-Carbon Innovation
ExxonMobil Faces California Lawsuit Over Plastic Wastage
CLB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Matador Closes $1.83B Ameredev Deal, Expands Delaware Footprint
Equinor Cancels Blue Hydrogen Export Plans to Germany Amid Low Demand
Targa's Shares Gain 76% Year to Date: Time to Buy or Hold?
Other News for CLB
CORE LABORATORIES' THIRD QUARTER 2024 WEBCAST AT 7:30 A.M. CDT / 8:30 A.M. EDT ON OCTOBER 24 2024
Innovative Approaches in Metabolic Dysfunction-Associated Steatohepatitis Clinical Research, Upcoming Webinar Hosted by Xtalks
The Top Five short crowded stocks in each U.S. sector
Warning: CLB is at high risk of performing badly
Tracking John Rogers' Ariel Investments Portfolio - Q2 2024 Update